SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses the Board's declaration of seventeen cash dividends on the Company's 9.50% Series A Perpetual Preferred Stock, with specified record dates, payment dates, and per-share amounts ranging from $0.1583 to $0.2639. This is a clear dividend distribution event disclosed via Item 7.01 and press release, materially affecting preferred shareholders' returns.
View raw filing on EDGAR →The filing discloses Boost Run Inc.'s financial and operational results for Q2 2026 (quarter ended June 30, 2026) via Item 2.02 (Results of Operations and Financial Condition). The earnings press release (Exhibit 99.1) reports Q2 revenue of $31.1 million (270% YoY increase), total contract value of $1.9 billion, and $120.2 million in unrestricted cash. This is the company's first earnings announcement as a public company following its May 8, 2026 business combination. The disclosure is material to investors assessing the registrant's financial performance and growth trajectory.
View raw filing on EDGAR →Dyadic International completed a registered direct offering of 3,625,000 shares at $0.795 per share combined with a concurrent private placement of 3,625,000 warrants to purchase additional shares, generating approximately $2.9 million in gross proceeds. This dilutive capital raise combines registered and unregistered equity securities and materially dilutes existing shareholders.
View raw filing on EDGAR →PAVmed issued a press release on August 14, 2026, announcing financial results for the fiscal quarter ended June 30, 2026, including operating expenses of $7.1 million, GAAP net loss of $5.5 million ($(0.87) per share), and cash position of $3.8 million as of June 30, 2026. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →The 8-K discloses first quarter fiscal 2027 financial results for PCS Edventures!, Inc. via a press release dated August 14, 2026 (Exhibit 99). The filing reports revenue of $1.74 million (down 28.2% year-over-year), gross margin of 62.8%, net income before tax of $0.10 million, and cash position of $2.65 million. This is a standard earnings release disclosure under Item 7.01 (Regulation FD Disclosure) with the press release furnished as Exhibit 99.
View raw filing on EDGAR →KonaTel received notice on August 13, 2026 that its 51%-owned subsidiary IM Telecom was cited by the FCC for alleged violations of Lifeline program rules. While the company asserts compliance and plans to respond to the FCC, this regulatory investigation into a material business line (the Lifeline program was IM Telecom's principal asset at acquisition) represents a legal/regulatory event that could adversely affect KonaTel's operations and financial position. The filing explicitly states "No assurance can be given that the FCC's noticed action regarding IM Telecom may not result in adverse consequences to KonaTel."
View raw filing on EDGAR →Clean Energy Technologies entered into a securities purchase agreement with Pacific Pier Capital II, LP to issue a convertible promissory note with principal amount of $178,410 for net funding of $143,000.80. The Note is convertible into common stock at 85% of the lowest 10-day VWAP, with an Exchange Cap of 2,000,000 shares pending shareholder approval. This is a dilutive equity issuance (convertible debt) raising capital through an unregistered private placement under Section 4(a)(2), which is material to investors as it signals potential equity dilution and capital-raising pressure.
View raw filing on EDGAR →The filing discloses a Settlement and Voluntary Share-Surrender Agreement resolving disputed matters concerning the Company's securities and historical transactions. The agreement involves voluntary surrender and cancellation of approximately 17.9 million pre-reverse-split shares (598,200 post-reverse-split shares) without monetary payment, plus cancellation of membership interests in a note-holder entity. While this involves share cancellation (a capital structure matter), the core event is a legal settlement of disputed claims as part of a "Compliance and Restitution" initiative, making it primarily a legal/regulatory matter rather than a pure financial or governance event. The settlement is material as it resolves historical disputes and affects share count and capitalization.
View raw filing on EDGAR →The filing discloses under Item 4.02 that HCW Biologics' Audit Committee concluded the Company's previously issued unaudited condensed financial statements for Q1 2026 should no longer be relied upon due to a material misstatement in earnings per share (EPS) calculation. The error involved misapplication of the two-class method for EPS, resulting in an overstatement of $0.80 per share ($2.19 reported vs. corrected amount). The Company identified a material weakness in internal controls over technical accounting review and intends to file a Form 10-Q/A to restate the affected financial statements.
View raw filing on EDGAR →The filing discloses financial results for Q2 2026 (three and six months ended June 30, 2026) via Item 2.02, including revenues, R&D expenses, G&A expenses, and net loss figures. The press release (Exhibit 99.1) announces "Second Quarter 2026 Business and Clinical Development Highlights and Financial Results," presenting both operational milestones and quarterly financial metrics. This is a standard earnings release disclosure material to investors assessing the company's financial performance and clinical progress.
View raw filing on EDGAR →The filing discloses results of a Special Meeting of Stockholders held on August 13, 2026, where shareholders voted on two proposals: (1) approval of a reverse stock split authorization (1-for-2 to 1-for-8 ratio, to be determined by the Board), which passed with 49,401,476 votes for vs. 10,935,417 against, and (2) an adjournment proposal, which also passed. This is a classic Item 5.07 shareholder vote results disclosure. The reverse stock split authorization is material to investors as it affects share structure and is typically undertaken to address delisting risks or improve stock price perception.
View raw filing on EDGAR →The filing discloses Item 5.07 results from a special stockholder meeting held on August 14, 2026, where shareholders voted on a reverse stock split proposal (approved 3,847,974 to 1,062,981) and an adjournment proposal. The reverse stock split authorization at a 1-for-2 to 1-for-50 ratio is material to investors as it directly affects share structure and is typically a signal of delisting risk mitigation or capital restructuring.
View raw filing on EDGAR →This exhibit is a research note / market commentary on industry developments in digital asset infrastructure (Morpho protocol adoption by Uniswap and Bitget, HashKey HSK Chain deployment, Base Layer-2 performance). While Black Titan Corp is mentioned only in a brief boilerplate "About" section as a company focused on "DAT+ strategy" supporting decentralized protocols, the exhibit itself does not disclose a discrete corporate event affecting Black Titan directly—no M&A, financing, executive change, or material operational announcement by Black Titan. Rather, it is third-party market analysis of ecosystem trends. However, given Black Titan's stated focus on supporting decentralized protocols and providing liquidity to them, and the material nature of the infrastructure shifts described (major CEX/DEX convergence, regulatory entry into APAC), this disclosure would likely be material to investors assessing Black Titan's strategic positioning and market opportunity. Classified as operational_other because it describes strategic market developments relevant to Black Titan's business domain, though it is not a discrete corporate action by Black Titan itself.
View raw filing on EDGAR →Lewis Liu resigned from his position as Chief Operating Officer of Phoenix Motor Inc. effective August 6, 2026. This is a clear executive departure under Item 5.02, as the COO is a named officer whose departure would affect a reasonable investor's assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →This exhibit is a press release announcing Foresight's financial results for Q2 2026 and H1 2026, including revenues, operating expenses, net loss, balance sheet highlights, and cash flow statements. The disclosure includes both GAAP and non-GAAP metrics and is dated August 14, 2026, consistent with a quarterly earnings announcement. While the company is unprofitable and burning cash, the disclosure of quarterly and interim financial results is a standard earnings release event.
View raw filing on EDGAR →The filing discloses Item 5.07 — submission of matters to a vote of security holders. The Majority Stockholder (Rennova Health, Inc., controlled by the CEO) approved by written consent an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio of 1:50 to 1:1,000, with the exact ratio to be determined by the Board solely for purposes of facilitating an uplisting to Nasdaq or NYSE American. This is a material shareholder action affecting capital structure and listing status.
View raw filing on EDGAR →The 8-K discloses Motorsport Games' financial results for Q2 2026 (quarter ended June 30, 2026) via Item 2.02 and an attached press release (Exhibit 99.1). The press release reports revenues of $3.5 million in Q2 2026 (up 36.6% YoY), six consecutive quarters of profitability, gross margin expansion to 84.7%, and significant growth in RaceControl subscription revenues (up 348.9% YoY). This is a standard quarterly earnings release material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →The 8-K discloses financial results for the three and six months ended June 30, 2026, with a press release attached as Exhibit 99.1. Item 2.02 explicitly states "On August 14, 2026, we issued a press release regarding our financial results for the three and six months ended June 30, 2026." The filing includes consolidated statements of comprehensive loss, revenue comparisons, gross profit analysis, and non-GAAP reconciliations—all standard components of an earnings release.
View raw filing on EDGAR →The filing discloses second quarter 2026 financial results for Barfresh Food Group, including revenue of $4.7 million (190% YoY increase), gross loss of $150,000, net loss of $1.9 million, and revised full-year 2026 guidance of $23–26 million revenue and negative $1.0–2.0 million Adjusted EBITDA. The press release (Exhibit 99.1) is the primary disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard vehicle for earnings releases. The filing includes management commentary, financial tables, and forward-looking statements typical of quarterly earnings announcements.
View raw filing on EDGAR →The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release dated August 14, 2026 reporting Q2 2026 financial results for Enveric Biosciences. The filing explicitly states the company "reported financial results for the second quarter ended June 30, 2026" and provides specific metrics including net loss of $3.0 million, loss per share of $0.76, and cash-on-hand of $8.3 million. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →Reed's received a notice from NYSE American on August 12, 2026, stating non-compliance with continued listing standards under Section 1003(a)(i) due to stockholders' deficit of $(1.5) million and losses in five consecutive fiscal years. The company has until November 29, 2027, to regain compliance or face delisting proceedings. The stock will trade with a ".BC" designation indicating "below compliance" status. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses Greenlane's financial results for the second quarter ended June 30, 2026 via Item 2.02 (Results of Operations and Financial Condition). The press release reports Q2 2026 net revenue of $82K, operating loss of $(3.3)M, and net loss of $(24.8)M, along with digital asset holdings and strategic metrics. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and digital asset treasury strategy.
View raw filing on EDGAR →BioRestorative Therapies suspended all orders and shipments of its biocosmeceutical product lines (ExoCR and BioX products) effective immediately, pending business review and regulatory assessment. This is a material operational event—a suspension of product sales affecting revenue-generating business lines—that does not fit the specific categories of workforce_reduction, material_litigation, or other named types. The company has not decided to discontinue the lines, but the immediate suspension pending regulatory review represents a significant operational disruption material to investors.
View raw filing on EDGAR →Mr. Zhiqiang Zhao resigned as a member of the board of directors and President, and Mr. Huan Li resigned as Chief Marketing Officer, effective immediately on August 11, 2026. While the filing also discloses the appointment of Mr. Bin Ma as director on August 12, the primary disclosed action is the departure of two executives from material roles (Board member and President; Chief Marketing Officer), with the Board eliminating these positions rather than filling them. The departure of a President and board member is material to investor assessment of leadership continuity.
View raw filing on EDGAR →The 6-K announces a 1-for-8 reverse stock split of Galmed's ordinary shares, effective August 19, 2026, reducing outstanding shares from approximately 8.3 million to 1.04 million. While a reverse split is a capital structure event with governance implications, it does not fit the specific event types (exec changes, M&A, debt, dilution, etc.). This is a material governance/capital structure action that would affect a reasonable investor's assessment of share count, trading mechanics, and potential delisting-risk mitigation, making it a governance_other event.
View raw filing on EDGAR →The filing discloses a private placement of 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof) together with warrants to purchase an additional 16,924,054 shares, raising approximately $4.0 million in gross proceeds. Item 1.01 describes entry into a material definitive securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a small-cap biotechnology company raising capital through a private placement.
View raw filing on EDGAR →The filing discloses results of GT Biopharma's Annual Meeting of Stockholders held on August 14, 2026, under Item 5.07. Six proposals were voted upon: election of four directors, ratification of auditors (Weinberg & Company, P.A.), advisory approval of executive compensation, approval of a reverse stock split (1-for-10 to 1-for-30 ratio) with authorized share reduction, and two amendments to the 2022 Omnibus Incentive Plan. All proposals passed. The reverse stock split authorization and equity plan amendments are material governance and capital structure decisions affecting shareholders.
View raw filing on EDGAR →This is a clear earnings release disclosing AgEagle's financial results for Q2 2026 (quarter ended June 30, 2026), including revenue of $2.7 million, gross margin of 50.6%, and cash position of $15.9 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing reports sequential revenue growth (nearly doubled from Q1) and provides forward guidance for the second half of 2026.
View raw filing on EDGAR →The 8-K discloses Nakamoto Inc.'s financial results for the second quarter ended June 30, 2026, via a press release dated August 13, 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The filing reports total operating revenue of $35.9 million, an operating loss of $149.1 million (driven primarily by $105.2 million in goodwill impairment and $48.7 million in mark-to-market losses on digital assets), and a net loss of $133.0 million. This is a standard quarterly earnings release disclosure, material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →DataMeds AI is announcing a voluntary one-time distribution of "Dream Bowl 2026 Meme Coin" tokens to shareholders at a ratio of 50 tokens per share, with a stated fair market value of $0.01 per token as of August 7, 2026. This is disclosed under Item 8.01 (Other Events) and constitutes a dividend or distribution to equity holders, meeting the definition of dividend_distribution. The distribution is material as it affects shareholder value and would be relevant to investor decision-making, though the unusual nature of distributing meme coins and the explicit disclaimers about their speculative value warrant careful consideration.
View raw filing on EDGAR →Worksport Ltd. received written notice from Nasdaq on August 13, 2026, that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until February 9, 2027, to regain compliance or face delisting. This is a classic Item 3.01 delisting-risk disclosure and is material to investors as it threatens the company's continued listing on Nasdaq.
View raw filing on EDGAR →The 8-K discloses Sidus Space's financial results for Q2 2026 ended June 30, 2026, via Item 2.02 (Results of Operations and Financial Condition). The press release (Exhibit 99.1) provides detailed quarterly revenue ($583K), net loss ($4.8M), cash position ($166.5M), and operational highlights including completion of launch qualification milestones and a $100M capital raise. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →The 8-K discloses Canton Strategic Holdings' financial and operating results for Q2 2026 under Item 2.02, with a press release attached as Exhibit 99.1. The filing reports the company's first operating revenue ($1.5M for Q2), including $1.3M from locking-as-a-service and $191K from validator operations, along with consolidated financial statements showing a net loss of $19.3M and significant digital asset holdings. This is a standard quarterly earnings release material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →The 8-K discloses financial results for Q2 2026 via Item 2.02 and an attached press release (Exhibit 99.1). While the press release emphasizes the completed Cataneo acquisition ($19.5M), the primary 8-K Item filed is 2.02 (Results of Operations and Financial Condition), and the filing announces the Form 10-Q submission. However, the acquisition is equally prominent and material. The earnings_release classification is chosen because Item 2.02 is the stated disclosure vehicle, though ma_activity would also be defensible given the acquisition's prominence and materiality.
View raw filing on EDGAR →Elong Power held an extraordinary general meeting on August 27, 2026, to solicit shareholder votes on ten proposals including ratification of a 45-for-1 share consolidation (effective August 10, 2026), amendments to the memorandum and articles of association, a substantial increase in authorized share capital from US$240M to US$288B, a share capital reduction and reorganization, and conditional further share consolidations tied to stock price thresholds. These governance matters materially affect the company's capital structure and shareholder dilution risk.
View raw filing on EDGAR →Item 5.07 discloses the results of the 2026 Annual Meeting of Shareholders held on August 12, 2026, including voting results for the election of trustee Steven S. Robson (7,090,809 votes for) and ratification of BCRG Group as independent auditors (7,447,535 votes for). This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →The filing discloses Upland Software's financial results for the second quarter ended June 30, 2026, issued via press release on August 14, 2026. The press release presents quarterly revenue ($49.1 million), net loss ($35.3 million GAAP), Adjusted EBITDA ($12.8 million), and forward guidance for Q3 and full-year 2026. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Jason F. Simone was appointed Chief Financial Officer effective August 10, 2026. The disclosure centers on the appointment of an officer to a named executive position, with background on his tenure and prior roles at the company. No compensatory arrangements are being entered into in connection with the appointment, and no departure of a prior CFO is mentioned, making this a straightforward executive appointment event.
View raw filing on EDGAR →This 8-K discloses the entry into an underwriting agreement for the issuance of commercial mortgage pass-through certificates (Series 2026-C36) with an aggregate initial principal amount of $619,061,000 in publicly offered certificates plus $81,433,284 in privately offered certificates. The filing describes the creation of a new direct financial obligation through the sale of debt securities backed by a pool of 31 fixed-rate mortgage loans. This is a material debt issuance event under Item 2.03, though structured as a securitization rather than traditional corporate debt.
View raw filing on EDGAR →This is a clear earnings release for the fiscal quarter ended June 30, 2026. The Item 2.02 disclosure announces quarterly financial results via a press release (Exhibit 99.1) that includes detailed financial statements, revenue figures ($2.5 million for Q2 2026), operating results (net loss of $30.3 million), and balance sheet data. The filing explicitly states "Solana Company Reports Second Quarter 2026 Financial Results" and provides comprehensive financial highlights and operational metrics typical of a quarterly earnings announcement.
View raw filing on EDGAR →CaliberCos announced the launch of its PURE Pickleball & Padel tokenized real estate investment offering, representing the first completed fund tokenization on its platform and the beginning of a ~$100 million tokenization program. This is a material operational and strategic milestone—a new product launch and technology implementation—that does not fit the specific categories of earnings, M&A, impairment, or other named event types. The disclosure centers on a business initiative and platform expansion rather than a routine administrative matter, making it material to investor assessment of the company's strategic direction and operational capabilities.
View raw filing on EDGAR →The Company issued 1,433,927 shares of Class A common stock to Liquidity Event Partners in reliance on Section 4(a)(2) exemption from registration, constituting an unregistered equity issuance. This is a material dilutive event for shareholders, particularly significant given the Company's recent IPO (May 19, 2026) and the substantial share count involved. The disclosure is properly filed under Item 3.02, which governs unregistered sales of equity securities.
View raw filing on EDGAR →LanzaTech issued a press release on August 14, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing revenue of $9.0 million, operating expenses of $11.7 million, net income of $184.3 million (driven by a non-cash unrealized gain on SGLT investment), and Adjusted EBITDA of $(7.6) million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →The filing discloses the appointment of Seth Cohen to the Board of Directors effective August 12, 2026, with the Board increasing from four to five directors. While the disclosure also mentions Cohen's standard director compensation and indemnification agreement, the principal action is his appointment to the Board and Compensation Committee. This is a material governance event for a newly public company (S-1 effective July 15, 2026) adding a director with significant federal nuclear policy expertise.
View raw filing on EDGAR →Space Exploration Technologies Corp. completed its acquisition of Anysphere, Inc. (Cursor) on August 14, 2026, through a subsidiary merger with Cursor surviving as a wholly owned subsidiary. The transaction involved an implied equity value of $60.0 billion and the issuance of approximately 391 million shares of Class A common stock plus assumed equity awards.
View raw filing on EDGAR →The filing discloses Cycurion's Q2 2026 financial results via a press release dated August 14, 2026, furnished as Exhibit 99.1. The press release reports revenue of $3.8 million (beating consensus of $3.62 million), EPS of $(0.41) (beating consensus of $(0.56)), and a nearly five-fold improvement in gross margin to 29.1%. The document includes detailed quarterly consolidated results of operations and non-GAAP reconciliations, which are hallmarks of an earnings release disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →This is a quarterly earnings release for Vistagen's fiscal year 2027 first quarter ended June 30, 2026, disclosing financial results including revenue of $1.5 million, R&D expense of $10.9 million, G&A expense of $3.9 million, and a net loss of $13.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated balance sheets and statements of operations, and the company provides forward-looking guidance on cash runway and expense trends.
View raw filing on EDGAR →Skye Bioscience has entered into a definitive transaction agreement to acquire the entire issued share capital of Redx Pharma Limited via a scheme of arrangement under U.K. law, resulting in a material change of control. The combined company will operate as Fibrx Therapeutics and trade on Nasdaq, with Redx shareholders owning approximately 46.17% and new investors owning approximately 48.45% of the combined entity post-closing, while Skye shareholders will own only approximately 5.38%. The transaction is accompanied by approximately $125 million in concurrent financings and is expected to close in Q4 2026, subject to shareholder and regulatory approvals.
View raw filing on EDGAR →In connection with the Redx acquisition, Skye is issuing unregistered equity securities comprising approximately $125 million in aggregate gross proceeds from a PIPE Financing (~$68M), Series A Financing (~$36M), and an Equity Line Facility warrant ($5M), issued under Section 3(a)(10) and Section 4(a)(2) exemptions. The concurrent financing will result in new investors owning approximately 48.45% of the combined company post-closing.
View raw filing on EDGAR →Punit Dhillon (President and CEO) and Tu Diep have entered into separation agreements with defined termination dates (August 31, 2027 and January 31, 2027 respectively) and severance arrangements in connection with the Redx acquisition transaction. Redx's management team will lead the combined company post-closing, signaling a leadership transition away from Skye's current executives.
View raw filing on EDGAR →